Literature DB >> 19622404

Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

Larry H Thompson1, John M Hinz.   

Abstract

The Fanconi anemia (FA) molecular network consists of 15 "FANC" proteins, of which 13 are associated with mutations in patients with this cancer-prone chromosome instability disorder. Whereas historically the common phenotype associated with FA mutations is marked sensitivity to DNA interstrand crosslinking agents, the literature supports a more global role for FANC proteins in coping with diverse stresses encountered by replicative polymerases. We have attempted to reconcile and integrate numerous observations into a model in which FANC proteins coordinate the following physiological events during DNA crosslink repair: (a) activating a FANCM-ATR-dependent S-phase checkpoint, (b) mediating enzymatic replication-fork breakage and crosslink unhooking, (c) filling the resulting gap by translesion synthesis (TLS) by error-prone polymerase(s), and (d) restoring the resulting one-ended double-strand break by homologous recombination repair (HRR). The FANC core subcomplex (FANCA, B, C, E, F, G, L, FAAP100) promotes TLS for both crosslink and non-crosslink damage such as spontaneous oxidative base damage, UV-C photoproducts, and alkylated bases. TLS likely helps prevent stalled replication forks from breaking, thereby maintaining chromosome continuity. Diverse DNA damages and replication inhibitors result in monoubiquitination of the FANCD2-FANCI complex by the FANCL ubiquitin ligase activity of the core subcomplex upon its recruitment to chromatin by the FANCM-FAAP24 heterodimeric translocase. We speculate that this translocase activity acts as the primary damage sensor and helps remodel blocked replication forks to facilitate checkpoint activation and repair. Monoubiquitination of FANCD2-FANCI is needed for promoting HRR, in which the FANCD1/BRCA2 and FANCN/PALB2 proteins act at an early step. We conclude that the core subcomplex is required for both TLS and HRR occurring separately for non-crosslink damages and for both events during crosslink repair. The FANCJ/BRIP1/BACH1 helicase functions in association with BRCA1 and may remove structural barriers to replication, such as guanine quadruplex structures, and/or assist in crosslink unhooking.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622404      PMCID: PMC2714807          DOI: 10.1016/j.mrfmmm.2009.02.003

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  280 in total

1.  The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells.

Authors:  L J Niedernhofer; J Essers; G Weeda; B Beverloo; J de Wit; M Muijtjens; H Odijk; J H Hoeijmakers; R Kanaar
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

2.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.

Authors:  Ronit I Yarden; Sherly Pardo-Reoyo; Magda Sgagias; Kenneth H Cowan; Lawrence C Brody
Journal:  Nat Genet       Date:  2002-02-11       Impact factor: 38.330

3.  BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.

Authors:  Rachel Litman; Min Peng; Zhe Jin; Fan Zhang; Junran Zhang; Simon Powell; Paul R Andreassen; Sharon B Cantor
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

Review 4.  Fanconi anemia.

Authors:  Grover C Bagby; Blanche P Alter
Journal:  Semin Hematol       Date:  2006-07       Impact factor: 3.851

5.  Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia.

Authors:  Elsa Callén; Enrique Samper; María J Ramírez; Amadeu Creus; Ricard Marcos; Juan J Ortega; Teresa Olivé; Isabel Badell; María A Blasco; Jordi Surrallés
Journal:  Hum Mol Genet       Date:  2002-02-15       Impact factor: 6.150

6.  Fanconi anemia proteins stabilize replication forks.

Authors:  Lily Chien Wang; Stacie Stone; Maureen Elizabeth Hoatlin; Jean Gautier
Journal:  DNA Repair (Amst)       Date:  2008-09-25

Review 7.  Fanconi anemia proteins and the s phase checkpoint.

Authors:  Pietro Pichierri; Filippo Rosselli
Journal:  Cell Cycle       Date:  2004-06-08       Impact factor: 4.534

Review 8.  Molecular pathogenesis of Fanconi anemia: recent progress.

Authors:  Toshiyasu Taniguchi; Alan D D'Andrea
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

9.  Telomere shortening in Fanconi anaemia demonstrated by a direct FISH approach.

Authors:  H Hanson; C G Mathew; Z Docherty; C Mackie Ogilvie
Journal:  Cytogenet Cell Genet       Date:  2001

10.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.

Authors:  Nazneen Rahman; Sheila Seal; Deborah Thompson; Patrick Kelly; Anthony Renwick; Anna Elliott; Sarah Reid; Katarina Spanova; Rita Barfoot; Tasnim Chagtai; Hiran Jayatilake; Lesley McGuffog; Sandra Hanks; D Gareth Evans; Diana Eccles; Douglas F Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2006-12-31       Impact factor: 38.330

View more
  70 in total

1.  Several tetratricopeptide repeat (TPR) motifs of FANCG are required for assembly of the BRCA2/D1-D2-G-X3 complex, FANCD2 monoubiquitylation and phleomycin resistance.

Authors:  James B Wilson; Eric Blom; Ryan Cunningham; Yuxuan Xiao; Gary M Kupfer; Nigel J Jones
Journal:  Mutat Res       Date:  2010-05-05       Impact factor: 2.433

Review 2.  Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair.

Authors:  Blanka Sengerová; Anderson T Wang; Peter J McHugh
Journal:  Cell Cycle       Date:  2011-12-01       Impact factor: 4.534

3.  CCAAT/enhancer binding protein delta (C/EBPdelta, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage.

Authors:  Jun Wang; Tapasree Roy Sarkar; Ming Zhou; Shikha Sharan; Daniel A Ritt; Timothy D Veenstra; Deborah K Morrison; A-Mei Huang; Esta Sterneck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

4.  Influence of homologous recombinational repair on cell survival and chromosomal aberration induction during the cell cycle in gamma-irradiated CHO cells.

Authors:  Paul F Wilson; John M Hinz; Salustra S Urbin; Peter B Nham; Larry H Thompson
Journal:  DNA Repair (Amst)       Date:  2010-07-01

5.  A novel link to base excision repair?

Authors:  David M Wilson; Michael M Seidman
Journal:  Trends Biochem Sci       Date:  2010-02-19       Impact factor: 13.807

6.  RAD51D- and FANCG-dependent base substitution mutagenesis at the ATP1A1 locus in mammalian cells.

Authors:  John M Hinz; Salustra S Urbin; Larry H Thompson
Journal:  Mutat Res       Date:  2009-03-18       Impact factor: 2.433

7.  EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

Authors:  Heike N Pfäffle; Meng Wang; Liliana Gheorghiu; Natalie Ferraiolo; Patricia Greninger; Kerstin Borgmann; Jeffrey Settleman; Cyril H Benes; Lecia V Sequist; Lee Zou; Henning Willers
Journal:  Cancer Res       Date:  2013-08-21       Impact factor: 12.701

8.  The DNA translocase FANCM/MHF promotes replication traverse of DNA interstrand crosslinks.

Authors:  Jing Huang; Shuo Liu; Marina A Bellani; Arun Kalliat Thazhathveetil; Chen Ling; Johan P de Winter; Yinsheng Wang; Weidong Wang; Michael M Seidman
Journal:  Mol Cell       Date:  2013-10-24       Impact factor: 17.970

9.  Spatiotemporally different DNA repair systems participate in Epstein-Barr virus genome maturation.

Authors:  Atsuko Sugimoto; Teru Kanda; Yoriko Yamashita; Takayuki Murata; Shinichi Saito; Daisuke Kawashima; Hiroki Isomura; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

10.  Bloom syndrome radials are predominantly non-homologous and are suppressed by phosphorylated BLM.

Authors:  Nichole Owen; James Hejna; Scott Rennie; Asia Mitchell; Amy Hanlon Newell; Navid Ziaie; Robb E Moses; Susan B Olson
Journal:  Cytogenet Genome Res       Date:  2015-02-28       Impact factor: 1.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.